D
David G. Maloney
Researcher at Fred Hutchinson Cancer Research Center
Publications - 528
Citations - 42318
David G. Maloney is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 95, co-authored 491 publications receiving 37057 citations. Previous affiliations of David G. Maloney include Stanford University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror,Michael B. Maris,Michael B. Maris,Rainer Storb,Rainer Storb,Frédéric Baron,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Barry E. Storer,Barry E. Storer +11 more
TL;DR: The new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival and will be useful for clinical trials and patient counseling before HCT.
Journal ArticleDOI
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
David G. Maloney,Antonio J. Grillo-Lopez,Christine A. White,David Bodkin,Russell J. Schilder,James A. Neidhart,Nalini Janakiraman,Kenneth A. Foon,Tina Marie Liles,Brian Dallaire,Ken Wey,Ivor Royston,Thomas A. Davis,Ronald Levy +13 more
TL;DR: Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
Journal ArticleDOI
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle,Laïla Aïcha Hanafi,Carolina Berger,Ted Gooley,Sindhu Cherian,Michael Hudecek,Daniel Sommermeyer,Katherine Melville,Barbara S. Pender,Tanya M Budiarto,Emily Robinson,Natalia N Steevens,Colette Chaney,Lorinda Soma,Xueyan Chen,Cecilia Yeung,Brent L. Wood,Daniel Li,Jianhong Cao,Shelly Heimfeld,Michael C. Jensen,Stanley R. Riddell,David G. Maloney +22 more
TL;DR: It is established that high CAR-T cell doses and tumor burden increase the risks of severe cytokine release syndrome and neurotoxicity, and serum biomarkers that allow testing of early intervention strategies in patients at the highest risk of toxicity are identified.
Journal ArticleDOI
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Peter A. McSweeney,Peter A. McSweeney,Peter A. McSweeney,Dietger Niederwieser,Dietger Niederwieser,Dietger Niederwieser,Judith A. Shizuru,Judith A. Shizuru,Judith A. Shizuru,Brenda M. Sandmaier,Brenda M. Sandmaier,Brenda M. Sandmaier,Arthur J. Molina,Arthur J. Molina,Arthur J. Molina,David G. Maloney,David G. Maloney,David G. Maloney,Thomas R. Chauncey,Thomas R. Chauncey,Thomas R. Chauncey,Ted Gooley,Ted Gooley,Ted Gooley,U Hegenbart,U Hegenbart,U Hegenbart,Richard A. Nash,Richard A. Nash,Richard A. Nash,Jerald P. Radich,Jerald P. Radich,Jerald P. Radich,John L. Wagner,John L. Wagner,John L. Wagner,Steven Minor,Steven Minor,Steven Minor,Frederick R. Appelbaum,Frederick R. Appelbaum,Frederick R. Appelbaum,William I. Bensinger,William I. Bensinger,William I. Bensinger,Eileen Bryant,Eileen Bryant,Eileen Bryant,Mary E.D. Flowers,Mary E.D. Flowers,Mary E.D. Flowers,George E. Georges,George E. Georges,George E. Georges,F. Carl Grumet,F. Carl Grumet,F. Carl Grumet,Hans-Peter Kiem,Hans-Peter Kiem,Hans-Peter Kiem,Beverly Torok-Storb,Beverly Torok-Storb,Beverly Torok-Storb,Cong Yu,Cong Yu,Cong Yu,Karl G. Blume,Karl G. Blume,Karl G. Blume,Rainer Storb,Rainer Storb,Rainer Storb +71 more
TL;DR: A novel allografting approach, based on the use of postgrafting immunosuppression to control graft rejection and GVHD, has dramatically reduced the acute toxicities of allogRAFTing.
Journal ArticleDOI
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
TL;DR: It is shown that anti-idiotype antibodies can be used to monitor B-cell tumors and to investigate the biology of these tumors, and the unique immunoglobulin variable region of each lymphoma clone may be considered a tumor-specific marker.